Navigation Links
The Pittsburgh Life Sciences Greenhouse Announces Additions to Nationally Recognized Executive Program
Date:12/8/2009

PITTSBURGH, Dec. 8 /PRNewswire/ -- The Pittsburgh Life Sciences Greenhouse (PLSG), the organization providing capital investments and customized company formation and business growth programs to the region's life sciences enterprises, announced that three life sciences industry leaders have joined the PLSG's Executive Program.

Joining the PLSG as Executives in Residence (EIRs) are Maureen Peszko and Michael Lang. Pierre E. Queiroz de Oliveira, Ph.D. has joined the Executive Program as an Executive Associate.

Maureen brings a strong background and senior management experience in the healthcare information technology segment. Most recently, Ms. Peszko was Senior Vice President, Strategy, Product Development, Government Affairs & Business Development at Sage Health Care. Prior to Sage Health Care, Maureen was Senior Vice President, Strategic Services and US Operations for Thomson Healthcare, a division of Thomson Reuters. From 1999 to 2007, Maureen served as Vice President & General Manager of Cerner Corporation, the leading US supplier of healthcare information technology solutions that optimize clinical and financial outcomes.

Maureen's career also includes positions with Deloitte Consulting and McKesson. Maureen holds a Bachelor of Arts Degree in Economics from Vanderbilt University and attended the Heinz Graduate School for Public Policy at Carnegie Mellon University.

Michael Lang joins the PLSG with 27 years of executive experience in the medical devices industry. He has an extensive background in general management, strategic business development, fundraising, marketing, product development and biomedical engineering. Most recently he served as the President of Galt Medical; a Dallas, TX based cardiovascular products company. His prior experience includes Vice President of Business Development at BioEnterprise in Cleveland, OH, Division General Manager at Avery Dennison Medical, Director of Market Development at wound healing company, Gliatech, Director of Product Development at Focal Interventional Therapeutics, Product Manager at Johnson & Johnson, Product Development Engineering Manager at CR Bard and Product Development Engineer at Gore and Associates, Medical Division. Michael holds a Bachelor of Science Degree in Biomedical Engineering from Northern Arizona University and a Master of Business Administration from Arizona State University.

Pierre E. Queiroz de Oliveira, Ph.D. has joined the PLSG as an Executive Associate focusing on the therapeutics segment. His experience is in Pharmacology and Drug Discovery. Pierre was selected as a Fellow in Molecular Pharmacology at the University of Pittsburgh and has received recognition for his outstanding research presentations at the University of Pittsburgh and the University of Bath, United Kingdom. Pierre holds a Master of Science Degree from the University of Bath and a Ph.D. in Molecular Pharmacology from the University of Pittsburgh.

"The availability and attraction of domain-specific talent to our regional life sciences community has been paramount to the PLSG's success," said John W. Manzetti, PLSG's President and Chief Executive Officer. "The world-class caliber of our Executive Program and the extensive background of our EIRs continue to build on our national reputation for attracting world-class talent to the region and building great life sciences companies." Manzetti continues, "By helping them build sustainable business models and secure capital investments, we make it possible for companies to deliver biomedical innovations to the marketplace more quickly and efficiently than they ever could alone."

Jim Jordan, PLSG's Vice President & Chief Investment Officer, adds, "Executives who have 'been there and done that' are deeply knowledgeable in the industry's commercialization strategies and tactics. They bring their 'Rolodex' of industry relationships to the region to accelerate our access to industry insiders and venture capital and forge relationships with future partners and acquirers." Mr. Jordan continues, "Our team will attend the 28th Annual JP Morgan Healthcare Conference, January 11-14, 2010. This invitation-only event gives us the opportunity to showcase the prowess of our regional life sciences companies to an impressive list of national venture capital organizations, building on PLSG's ongoing mission to build sustainable sources of funding to fuel the future of our life sciences community."

Since inception, thirty-two life sciences experts have participated in the PLSG Executive Program. Eight of those executives remain active in the PLSG Executive Program and twenty remain in western Pennsylvania's life sciences community -- twelve as CEOs and eight as C-Suite and Executive Team members.

About the Pittsburgh Life Sciences Greenhouse (PLSG)

The Pittsburgh Life Sciences Greenhouse (PLSG) provides capital investments and customized company formation and business growth services to western Pennsylvania's life sciences enterprises. The PLSG supports biosciences companies with promising innovations in the following concentrations: Biotechnology Tools, Diagnostics, Healthcare IT, Medical Devices and Therapeutics. The PLSG is propelling the sustainable growth of the region's life sciences economy by accelerating research and technology commercialization with seed and early-stage companies; connecting investors with their Investment Portfolio companies; expanding established life sciences ventures and relocating biomedical companies to Pennsylvania. For more information, visit www.plsg.com .

SOURCE Pittsburgh Life Sciences Greenhouse


'/>"/>
SOURCE Pittsburgh Life Sciences Greenhouse
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
2. The Pittsburgh Life Sciences Greenhouse Adds to Its Investment Portfolio
3. The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors
4. The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh
5. The Pittsburgh Life Sciences Greenhouse Invests $100,000 in ParentPlus
6. The Pittsburgh Life Sciences Greenhouse Tops $10M in Company Investments
7. Court Determines that University of Pittsburgh and Artecel Have Sole Rights to Adipose-Derived Stem Cell Patent
8. Pittsburgh Region Middle School Students Participate in Hands-on Tissue Engineering Summer Camp
9. Childrens Hospital of Pittsburgh of UPMC Receives Prestigious Recognition for Patient Safety Efforts in National Survey
10. Pittsburgh Technology Council Announces Technology 50
11. Opening Dedication of the New John G. Rangos Sr. Research Center at the New Childrens Hospital of Pittsburgh of UPMC Campus in Lawrenceville
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):